Evidence map›Paper›PMID 27652202›Full record

ReviewTranslational lung cancer research2016

From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel.

Chunxia Su, Mathias Meyer, Robert Pirker, Wieland Voigt, Jingyun Shi, Lothar Pilz, Rudolf M Huber, Yilong Wu, Jinghong Wang, Yonglan He and 10 more

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03317080 (A Study of the Value of Dynamic Monitoring Circulating Tumor DNA in Patients With Lung Cancer for Post-Operative Evaluation,Therapy Response Assessment,Relapse Prediction and Defining Molecular Phenotypes.), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03317080 unknown statusnot on this mapstarted 2017, after this paper: background citation

A Study of the Value of Dynamic Monitoring Circulating Tumor DNA in Patients With Lung Cancer for Post-Operative Evaluation,Therapy Response Assessment,Relapse Prediction and Defining Molecular Phenotypes.

TypeobservationalSponsorWest China HospitalRan2017 to 2023Enrolled400ConditionsLung Cancer
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Implementation of sodium alginate-FeScientific reports · 2022
    Article
  4. Article
  5. Observational
  6. How to diagnose pulmonary nodules: from screening to therapy.Translational lung cancer research · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 3 countries.

Chunxia SuDepartment of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200090, China ;
Mathias MeyerInstitute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany ;
Robert PirkerDepartment of Medicine, Medical University of Vienna, Vienna, Austria ;
Wieland VoigtMedical Innovation and Management, Steinbeis University Berlin, Germany ;
Jingyun ShiRadiology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200090, China.
Lothar PilzDivision of Thoracic Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany ;
Rudolf M HuberDivision of Respiratory Medicine and Thoracic Oncology, Ludwig-Maximilians-University of Munich Thoracic Oncology Centre, Munich, Germany ;
Yilong WuGuangdong General Hospital, Lung Cancer Institute, Guangzhou 510080, China ;
Jinghong WangDepartment of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China ;
Yonglan HeDepartment of Radiology, Beijing Union Medical College Hospital, Beijing 100730, China ;
Xuan WangDepartment of Radiology, Beijing Union Medical College Hospital, Beijing 100730, China ;
Jian ZhangDepartment of Respiratory, the Fourth Military Medical University Xijing Hospital, Xi'an 710032, China ;
Xiuyi ZhiDepartment of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China ;
Meiqi ShiDepartment of Oncology, Tumor Hospital of Jiangsu Province, Nanjing 210000, China ;
Bo ZhuDepartment of Oncology, Xinqiao Hospital of Third Military Medical University, Chongqing 400037, China ;
Stefan S SchoenbergInstitute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany ;
Thomas HenzlerInstitute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany ;
Christian ManegoldDivision of Thoracic Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Caicun ZhouDepartment of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200090, China ;
Eric Dominic RoessnerDivision of Surgical Oncology and Thoracic Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Tongji University · CNHeidelberg University · DEShanghai Pulmonary Hospital · CNSteinbeis University Berlin · DEUniversity Hospital Heidelberg · DEUniversity Medical Centre Mannheim · DEGuangdong General Hospital · CNJiangsu Cancer Hospital · CNLudwig-Maximilians-Universität München · DEMedical University of Vienna · ATUnion Hospital · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first Chinese-German Lung Cancer Expert Panel was held in November 2015 one day after the 7th Chinese-German Lung Cancer Forum, Shanghai. The intention of the meeting was to discuss strategies for the diagnosis and treatment of lung cancer within the context of lung cancer screening. Improved risk classification criteria and novel imaging approaches for screening populations are highly required as more than half of lung cancer cases are false positive during the initial screening round if the National Lung Screening Trial (NLST) demographic criteria [≥30 pack years (PY) of cigarettes, age ≥55 years] are applied. Moreover, if the NLST criteria are applied to the Chinese population a high number of lung cancer patients are not diagnosed due to non-smoking related risk factors in China. The primary goal in the evaluation of pulmonary nodules (PN) is to determine whether they are malignant or benign. Volumetric based screening concepts such as investigated in the Dutch-Belgian randomized lung cancer screening trial (NELSON) seem to achieve higher specificity. Chest CT is the best imaging technique to identify the origin and location of the nodule since 20% of suspected PN found on chest X-ray turn out to be non-pulmonary lesions. Moreover, novel state-of-the-art CT systems can reduce the radiation dose for lung cancer screening acquisitions down to a level of 0.1 mSv with improved image quality to novel reconstruction techniques and thus reduce concerns related to chest CT as the primary screening technology. The aim of the first part of this manuscript was to summarize the current status of novel diagnostic techniques used for lung cancer screening and minimally invasive treatment techniques for progressive PNs that were discussed during the first Chinese-German Lung Cancer. This part should serve as an educational part for the readership of the techniques that were discussed during the Expert Panel. The second part summarizes the consensus recommendations that were interdisciplinary discussed by the Expert Panel.

Indexed as

Lung cancermodern imagingmolecular markerspulmonary nodules (PN)response assessmentscreening, minimally-invasive therapy

Identifiers

PMID27652202
PMCPMC5009083
OpenAlexW2507547634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.